Cockermouth GP surgery still needs to improve after CQC warning
A GP practice has been told it still needs to improve, almost a year after a watchdog issued a warning about its leadership.Castlegate and Derwent Surgery in Cockermouth, Cumbria, has maintained an overall rating of "requires improvement" following an inspection by the Care Quality Commission (CQC).It found the practice's leadership had improved from being judged "inadequate" to "requires improvement". The same score was given for its effectiveness, however this had dropped from "good".The surgery said while the rating highlighted some areas where it had fallen short of the "high standards" it aimed to provide, it also acknowledged "many of the improvements" made.
Inspectors said patients were "dissatisfied with the ability to contact the practice via telephone" and found it difficult to make appointments.However, they said once they got an appointment they were treated with "dignity and respect".
'Inappropriately' triaged
Last year, Castlegate and Derwent Surgery was told by inspectors that its leadership had failed to establish processes to "monitor and improve the quality and safety of care provided".The new report, published last week, and based on an inspection carried out at the start of the year, said the practice team did not always understand the challenges and the needs of people and their communities.Although the practice had shared an analysis of "areas of risk and areas of improvement", inspectors said they "did not see evidence of these improvements being embedded within practice"."Staff told us they were aware of conflict and issues within the established clinical team," the report said."This team was not working effectively together to create a positive, inclusive and supportive culture."Inspectors said there were issues with staffing, with patients being "inappropriately" triaged on the phone.They added: "The service did not always plan and deliver people's care and treatment with them, including what was important and mattered to them."However, they said the practice supported people to "live healthier lives" and "reduce their future needs for care and support".The surgery said it had taken the CQC's findings "very seriously" and had already implemented changes, such as a new triage system and more staff training.It also plans to change how appointment diaries are run to increase face-to-face appointments and introduce regular quality audits.A spokesperson said: "We want to assure our patients and the wider community that we are fully committed to addressing these issues and enhancing the quality of care we deliver."They added the practice welcomed patients' feedback to improve the service."We deeply regret any distress or inconvenience caused by the issues highlighted in the CQC report," the spokesperson added.
Follow BBC Cumbria on X, Facebook, Nextdoor and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
UK vaccine chiefs suspend newly approved jab for over 65s - reports of two deaths and 21 severe reactions
UK vaccine chiefs have suspended a newly approved jab from being given to people aged over 65, after reports of two deaths and 21 severe reactions. The vaccine protects against the potentially fatal Chikungunya virus, which is typically found in the subtropical regions of the Americas, Africa, Southeast Asia, India, the Pacific Region and increasingly in Europe. Although the virus isn't found in the UK, Britons can become infected while overseas and fall ill when they return home. While the jab, called IXCHIQ, is approved in the UK it has yet to be rolled out, so there are no immediate safety concerns, British regulators said. The suspension follows global reports of 23 serious adverse effects in older people, including two deaths. It followed two fatalities in the French island La Réunion—in the Indian Ocean—where a vaccination campaign is underway following a recent Chikungunya outbreak. One death involved an 84-year-old man who developed encephalitis—a swelling of the brain—after having an adverse reaction to the vaccine. The other was a 77-year-old man living with Parkinson's disease who reportedly began finding swallowing increasingly difficult after the jab. This is believed to have triggered aspiration pneumonia, a serious infection caused by food, saliva and/or vomit entering the lungs rather than the stomach. The European Medicines Agency, who are reviewing the chikungunya vaccine following the reports, has not yet revealed the time between the dead men receiving the jabs and their deaths. There are no changes in the recommendations for vaccination with IXCHIQ for people aged between 18 and 64. The vaccine is currently not approved for use in individuals with a weakened immune system as a result of disease or medical therapy. The decision by the Commission on Human Medicines (CHM) is a precautionary measure until a further safety review has been concluded. The Medicines and Healthcare products Regulatory Agency (MHRA) is working with the vaccine manufacturer Valneva. The majority of people infected with Chikungunya develop a sudden fever and severe pain in multiple joints. Other symptoms may include headache, muscle pain, joint swelling, or rash. The virus is spread to humans by bites from infected mosquitoes, but cannot be passed from person-to-person. Symptoms typically resolve within 7 to 10 days, and most patients make a full recovery. However, in some cases the joint pain and arthritis may persist for several months or even years. Occasional cases of eye, neurological and heart complications have been reported, as well as gastrointestinal complaints. A small number of people may develop a severe version of the disease, which can lead to multiple organ failure and death. Severe symptoms and deaths are rare and usually occur in young babies or elderly people with coexisting health problems. There is no specific antiviral treatment for Chikungunya but medications (such as paracetamol) for fever and pain can be used to alleviate these symptoms. There are currently two vaccinations which protect against the virus; IXCHIQ for those aged between 18 and 64 and Vimkunya for those 12 years and older. A recent outbreak in La Réunion has seen over 47,500 cases of the virus, with 12 fatalities. In 2024 there were 112 Chikungunya cases reported in England, Wales and Northern Ireland from travellers arriving to or returning to Britain—this was nearly one-and-a-half times the level recorded in the previous year.
The Independent
an hour ago
- The Independent
Parents whose sons are losing ability to walk face ‘nightmare' battle with NHS
Parents whose sons are losing the ability to walk have described the 'nightmare' battle they face with the NHS to access a free drug. The medicine givinostat can slow progress of Duchenne muscular dystrophy – keeping children on their feet for longer – and is being offered for free by a drug firm while it goes through the process of NHS approval. However, only some NHS trusts across the UK, and few in England, are giving the drug despite it being part of an early access programme since November. Families are now facing a 'cruel' postcode lottery over who gets the medicine and are in a race against time, according to the charity Duchenne UK. Some NHS trusts are refusing to supply the drug while others delay it by drawing up lists of who they think should get it first. NHS trusts say they need to pay for monitoring the drug – around £1,900 per year per patient – out of their own budget. In desperation, parents have met with Health Secretary Wes Streeting to try and speed up access. According to the Government, it is up to individual NHS trusts to decide whether to provide the drug. Duchenne UK is supporting families in their fight for givinostat, including Rosie and Pete Day, an investment manager, and their 10-year-old son Jasper, from Horsham, West Sussex. The Day family have twins Jasper and Arabella, aged 10, and two older daughters. Both Jasper and Arabella have Duchenne, with Arabella a carrier of the genetic disorder and Jasper the most affected, as the condition mostly affects boys. The drug, developed by ITF Pharma UK, is only being given under the early access programme to children who are still able to walk. Mrs Day told the PA news agency: 'We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper. 'We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child. 'It's so close – and yet we're stuck. 'We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there. 'We're on the finishing line to get something that will make a difference and we can't quite get there because of the system we're in. 'The drug is not going to cure it, but it will give him the childhood you would wish to give your child – to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do. 'We can't give it because it we're stuck, even though it's free and it's there – we can't give it. 'It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck. 'It's a lottery, basically, depending on where you are in the country … and within NHS trusts themselves.' Jasper is under the care of the Evelina London Children's Hospital, which is only now starting to contact patients and is drawing up a priority list for who gets the drug first. 'Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles,' Mrs Day said. 'Two weeks ago, he asked me, 'When will I get the drug, mummy?' 'We're stuck in a situation over who's going to make those decisions regarding who gets the drug – of whether Jasper gets it or another boy. 'For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria.' She added: 'If Jasper stops walking, we're not going to get that back. 'Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night. 'Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results – that is what is standing in our way.' Mrs Day said it was unclear how the Evelina is 'going to make a fair choice' because knowing who will lose mobility is not an exact science. Mr Day said the process is 'hugely subjective' because there is no linear decline in the condition and the decisions made by NHS trusts could end up being 'completely wrong'. According to Duchene UK, boys whose condition is getting worse risk falling off the list entirely while waiting for the drug. Around 500 boys in the UK are eligible for givinostat, which can be taken at home like Calpol, with hospitals then doing follow-up blood tests of around eight in the first year, followed by twice a year thereafter. Children may also need an ECG, though these are already part of routine Duchenne monitoring. Emily Reuben and Alex Johnson, founders of Duchenne UK, said: 'As time ticks by, more boys are losing out on their chance to access givinostat. 'This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families. 'The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys.' To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff. Leicester Royal Infirmary was the first trust in England to give the drug, but the Evelina has not yet, and neither have trusts in Manchester, Liverpool and Newcastle. Great Ormond Street Hospital is working to supply the drug. A spokesman for the Evelina said: 'We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months. 'Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon.' An NHS spokesman said: 'The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients. 'NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme.'
TTG
2 hours ago
- TTG
'It's comfortable and cosy': why working from bed is key to this agent's success
A travel agency owner has called for more compassion for homeworkers, arguing that she manages her company more efficiently from her house – and indeed her bed – than she ever could from an office. Paula Hansen runs World Accessible Holidays, which specialises in travel for disabled clients, entirely from her home in Wales. Like many agents, she believes a remote model enables her to maintain a healthier work-life balance and be overall more productive. But for Hansen, homeworking isn't just a perk – it's a necessity. The mother-of-one lives with fibromyalgia, a chronic disorder that causes pain in muscles and soft tissues all over the body. Other symptoms include fatigue, brain fog and sleep disturbances, all of which can significantly affect the individual's ability to work – and makes working from an office almost impossible. In 2023, 136,000 claimants of PIP (Personal Independence Payment) listed fibromyalgia as their main disabling condition. Many people in employment may also require additional sick leave and/or reduced hours, due to the severe and often volatile nature of their symptoms. But Hansen is determined not to let her fibromyalgia limit her potential as a business woman. Three years on from her diagnosis, she has developed a sturdy kit of tools for maintaining her productivity – including working from bed. 'Why shouldn't you work from bed?' Hansen tells TTG Luxury. 'It's comfortable and cosy, and you're probably working more effectively because you're relaxed.' The self-proclaimed 'bedpreneur' says that working from bed is also preferable to a desk, which tends to flare up her symptoms: 'All of the pain from my fibromyalgia is from the hips upwards, so my back will hurt if I'm sitting on a chair for too long.' Hansen's work hours are also atypical, beginning at around 10am and ending at nearly midnight. 'My pain levels are highest in the morning, so I'll do some hours after 10am, and then if I'm tired, I'll go and have a sleep, and then resume work when I wake up,' she explains. 'So it is more like a nine to 11 schedule, with lots of sleep breaks in between.' She also uses meditation and ice packs, along with painkillers when necessary, to further alleviate her symptoms. 'Why shouldn't you work from bed? It's comfortable and cosy' As well as helping her to manage pain more effectively, working from home has also been hugely beneficial for Hansen's concentration. Without the usual office disruptions, she says she can focus for longer and thus, complete tasks faster. This lack of distractions can be especially valuable for people with fibromyalgia, 80% of whom will experience issues with memory and attention. While Hansen's condition has undoubtedly made work more challenging, it has also instilled in her a great deal of empathy for her clients. The Cardiff native knows all too well the obstacles of travelling with mobility issues; as well as causing extreme tiredness, her fibromyalgia prevents her from sitting in one position for extended periods of time, which makes driving and flying particularly difficult. Hansen also has a teenage son with cerebral palsy, a neurological condition that causes muscle weakness and impaired mobility. While Evan can walk short distances, he requires a wheelchair and is unable to travel without assistance. Flying can be especially 'nightmarish', says Hansen, due to the lack of consideration from other passengers boarding the plane. It's this first-hand experience of disability that has given her the determination to continue advocating for disabled travellers – even when she's in severe pain. Hansen arranges all types of trips for her clients, from city breaks and beach holidays to safaris and honeymoons. To achieve this, she partners with specialist suppliers who can provide medical equipment, adapted transport and accessible accommodation. The disability of her customers varies, but each one has a dream of travelling without barriers. For many, it's their first holiday after a serious illness or accident. The additional requirements create extra work for Hansen, but having witnessed the life-changing power of travel for individuals with disabilities, she says 'it's all worthwhile'. 'When you have a client tell you they've gotten into the sea for the first time because you've recommended a hotel with a sea track, that is much better than just someone saying, 'I've had a great holiday,'' she explains. 'It's so rewarding.'
